{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:31:37Z","timestamp":1792697497075,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-024-21247-5","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:22:51Z","timestamp":1735950171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Economic burden of Type 2 diabetes in Iran in 2022"],"prefix":"10.1186","volume":"25","author":[{"given":"Amin","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshad","family":"Goharimehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Darvishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ensieh Nasli","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Shafiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Ostovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajabali","family":"Daroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"12","key":"21247_CR1","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.2337\/dci23-0035","volume":"46","author":"K Khunti","year":"2023","unstructured":"Khunti K, et al. Diabetes and multiple long-term conditions: A review of our current global health challenge. Diabetes Care. 2023;46(12):2092\u2013101.","journal-title":"Diabetes Care"},{"key":"21247_CR2","unstructured":"Organization, W.H. Diabetes. 2023 5 April 2023]; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"21247_CR3","doi-asserted-by":"crossref","unstructured":"Abdul Basith Khan, M., et al., Epidemiology of type 2 diabetes\u2014global burden of disease and forecasted trends. J Epidemiol Global Health. 2020;(1):107\u2013111.","DOI":"10.2991\/jegh.k.191028.001"},{"key":"21247_CR4","unstructured":"federation, i.d. Diabetes facts and figures. 2024; Available from: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/."},{"issue":"10365","key":"21247_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, et al. Type 2 diabetes. Lancet. 2022;400(10365):1803\u201320.","journal-title":"Lancet"},{"key":"21247_CR6","unstructured":"uptodate. Patient education: Type 2 diabetes: Overview (Beyond the Basics). 2024 [cited May 20, 2024; Available from: https:\/\/www.uptodate.com\/contents\/type-2-diabetes-overview-beyond-the-basics\/print."},{"key":"21247_CR7","unstructured":"Iran, N.I.o.H.R.o., Atlas of STEPwise Approach to Noncommunicable Disease (NCD) Risk Factor Surveillance (STEPs) 2021. (Spring, 2022). p. 1\u2013631."},{"issue":"7","key":"21247_CR8","doi-asserted-by":"publisher","first-page":"e0132505","DOI":"10.1371\/journal.pone.0132505","volume":"10","author":"M Javanbakht","year":"2015","unstructured":"Javanbakht M, et al. Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and Bayesian meta-analysis. PLoS ONE. 2015;10(7):e0132505.","journal-title":"PLoS ONE"},{"issue":"5","key":"21247_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2337\/dc17-1962","volume":"41","author":"C Bommer","year":"2018","unstructured":"Bommer C, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41(5):963\u201370.","journal-title":"Diabetes Care"},{"key":"21247_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13300-015-0096-0","volume":"6","author":"H Hu","year":"2015","unstructured":"Hu H, et al. A systematic review of the direct economic burden of type 2 diabetes in China. Diabetes Therapy. 2015;6:7\u201316.","journal-title":"Diabetes Therapy"},{"issue":"6","key":"21247_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S2213-8587(17)30097-9","volume":"5","author":"C Bommer","year":"2017","unstructured":"Bommer C, et al. The global economic burden of diabetes in adults aged 20\u201379 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423\u201330.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"21247_CR12","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.3390\/ijerph191912611","volume":"19","author":"MD Butt","year":"2022","unstructured":"Butt MD, et al. Cost of illness analysis of type 2 diabetes mellitus: the findings from a lower-middle income country. Int J Environ Res Public Health. 2022;19(19):12611.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"21247_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1120","volume":"6","author":"H Jalilian","year":"2023","unstructured":"Jalilian H, et al. Economic burden of type 2 diabetes in Iran: A cost-of-illness study. Health Sci Rep. 2023;6(2): e1120.","journal-title":"Health Sci Rep"},{"issue":"1","key":"21247_CR14","first-page":"35","volume":"5","author":"F Abolhasani","year":"2005","unstructured":"Abolhasani F, et al. Burden of diabetes and its complications in Iran in year 2000. Iran J Diabetes Metab. 2005;5(1):35\u201348.","journal-title":"Iran J Diabetes Metab"},{"key":"21247_CR15","unstructured":"Global burden of disease collaborative network. global burden of disease study 2021 (GBD 2021) results. Seattle, United States: Institute for health metrics and evaluation (IHME), 2022. Available from https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"key":"21247_CR16","doi-asserted-by":"crossref","unstructured":"Shiri, M.S., et al., Hospitalization expenses and influencing factors for inpatients with ischemic heart disease in Iran: a retrospective study. Health Scope, 2022. 11(1).","DOI":"10.5812\/jhealthscope.117711"},{"issue":"8","key":"21247_CR17","doi-asserted-by":"publisher","first-page":"e074711","DOI":"10.1136\/bmjopen-2023-074711","volume":"14","author":"Z Kazemi","year":"2024","unstructured":"Kazemi Z, et al. Estimation and determinants of direct hospitalisation cost for coronary heart disease in a low-middle-income country: evidence from a nationwide study in Iranian hospitals. BMJ Open. 2024;14(8):e074711.","journal-title":"BMJ Open"},{"issue":"12","key":"21247_CR18","doi-asserted-by":"publisher","first-page":"e067573","DOI":"10.1136\/bmjopen-2022-067573","volume":"12","author":"Z Kazemi","year":"2022","unstructured":"Kazemi Z, et al. Estimation and predictors of direct hospitalisation expenses and in-hospital mortality for patients who had a stroke in a low-middle income country: evidence from a nationwide cross-sectional study in Iranian hospitals. BMJ Open. 2022;12(12):e067573.","journal-title":"BMJ Open"},{"key":"21247_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.vhri.2020.04.004","volume":"24","author":"MS Movahed","year":"2021","unstructured":"Movahed MS, et al. Economic burden of stroke in Iran: a population-based study. Value in Health Regional Issues. 2021;24:77\u201381.","journal-title":"Value in Health Regional Issues"},{"issue":"1","key":"21247_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13561-022-00377-9","volume":"12","author":"RS Shahtaheri","year":"2022","unstructured":"Shahtaheri RS, et al. Long-term cost-effectiveness of quality of diabetes care; experiences from private and public diabetes centers in Iran. Heal Econ Rev. 2022;12(1):44.","journal-title":"Heal Econ Rev"},{"key":"21247_CR21","doi-asserted-by":"crossref","unstructured":"Kazemi, Z., et al., Hidden health effects and economic burden of stroke and coronary heart disease attributed to ambient air pollution (PM2. 5) in Tehran, Iran: Evidence from an assessment and forecast up to 2030. Ecotoxicology and Environmental Safety, 2024;286:117158.","DOI":"10.1016\/j.ecoenv.2024.117158"},{"key":"21247_CR22","unstructured":"Food and Drug Organization of Iran, The pharmaceutical statistics of 2022, accessible through: https:\/\/publicbi.fda.gov.ir\/Reports\/powerbi\/Iran_Drug_Report1401?rs:embed=true."},{"issue":"1","key":"21247_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/dci23-0085","volume":"47","author":"ED Parker","year":"2024","unstructured":"Parker ED, et al. Economic costs of diabetes in the US in 2022. Diabetes Care. 2024;47(1):26\u201343.","journal-title":"Diabetes Care"},{"issue":"10","key":"21247_CR24","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","volume":"40","author":"V Jha","year":"2023","unstructured":"Jha V, et al. Global Economic Burden Associated with chronic kidney disease: a pragmatic review of medical costs for the Inside CKD Research Programme. Adv Ther. 2023;40(10):4405\u201320.","journal-title":"Adv Ther"},{"issue":"1","key":"21247_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12882-023-03056-x","volume":"24","author":"JD Kampmann","year":"2023","unstructured":"Kampmann JD, et al. Prevalence and incidence of chronic kidney disease stage 3\u20135\u2013results from KidDiCo. BMC Nephrol. 2023;24(1):17.","journal-title":"BMC Nephrol"},{"key":"21247_CR26","unstructured":"Control, C.f.D. and Prevention, Chronic kidney disease in the United States, 2021. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2021."},{"key":"21247_CR27","unstructured":"Statistical Centre of Iran, Labor Force Survey Results in 2022, Available at: https:\/\/amar.org.ir\/statistical-information\/statid\/28352."},{"key":"21247_CR28","unstructured":"World Health Organization, Global Health Observatory, Life tables by country. Available from https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/gho-ghe-life-tables-by-country."},{"key":"21247_CR29","unstructured":"World Bank. \"DEC Alternative Conversion Factor (Atlas Method) for Iran.\" Data, 2000\u20132023, https:\/\/data.worldbank.org\/indicator\/PA.NUS.ATLS."},{"issue":"3","key":"21247_CR30","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.dsx.2019.05.018","volume":"13","author":"Y Moradi","year":"2019","unstructured":"Moradi Y, et al. Complications of type 2 diabetes in Iranian population: An updated systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(3):2300\u201312.","journal-title":"Diabetes Metab Syndr"},{"key":"21247_CR31","unstructured":"Federation, I.D. Diabetes around the world in 2021. 2024; Available from: https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/11\/IDFDA10-global-fact-sheet.pdf."},{"issue":"5","key":"21247_CR32","first-page":"1071","volume":"52","author":"A Shojaee","year":"2023","unstructured":"Shojaee A, et al. Utilization Trend of Parenteral Antidiabetic Drugs in Type 2 Diabetic Patients Covered by Iran Health Insurance Organization from 2011 to 2030. Iran J Public Health. 2023;52(5):1071.","journal-title":"Iran J Public Health"},{"key":"21247_CR33","unstructured":"Singh, J., Economic burden of diabetes. Muruganathan A, Geetha T, editors. Vol. 23. Medicine Update. Association of Physicians of India, India, 2013. 205."},{"issue":"2","key":"21247_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.12968\/bjhc.2014.20.2.60","volume":"20","author":"D Meetoo","year":"2014","unstructured":"Meetoo D. Diabetes: complications and the economic burden. Br J Healthc Manag. 2014;20(2):60\u20137.","journal-title":"Br J Healthc Manag"},{"issue":"4","key":"21247_CR35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2337\/dc12-2625","volume":"36","author":"AD Association","year":"2013","unstructured":"Association AD. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033\u201346.","journal-title":"Diabetes Care"},{"key":"21247_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12992-014-0080-x","volume":"10","author":"CA Yesudian","year":"2014","unstructured":"Yesudian CA, et al. The economic burden of diabetes in India: a review of the literature. Glob Health. 2014;10:1\u201318.","journal-title":"Glob Health"},{"issue":"6","key":"21247_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5539\/gjhs.v7n6p187","volume":"7","author":"O Faraji","year":"2015","unstructured":"Faraji O, et al. Policies and Programs for Prevention and Control of Diabetes in Iran: A Document Analysis. Glob J Health Sci. 2015;7(6):187\u201397.","journal-title":"Glob J Health Sci"},{"key":"21247_CR38","first-page":"6908","volume":"12","author":"S Sadeghi","year":"2023","unstructured":"Sadeghi S, et al. Barriers Toward the National Program for Prevention and Control of Diabetes in Iran: A Qualitative Exploration. Int J Health Policy Manag. 2023;12:6908.","journal-title":"Int J Health Policy Manag"},{"key":"21247_CR39","doi-asserted-by":"publisher","first-page":"1062903","DOI":"10.3389\/fpubh.2023.1062903","volume":"11","author":"X Liu","year":"2023","unstructured":"Liu X, Zhang L, Chen W. Trends in economic burden of type 2 diabetes in China: Based on longitudinal claim data. Front Public Health. 2023;11:1062903.","journal-title":"Front Public Health"},{"issue":"6","key":"21247_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14737167.2020.1837626","volume":"20","author":"J Kjellberg","year":"2020","unstructured":"Kjellberg J, et al. Short-term societal economic burden of first-incident type 2 diabetes-related complications\u2013a nationwide cohort study. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):577\u201386.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"21247_CR41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40273-023-01258-7","volume":"41","author":"D Abushanab","year":"2023","unstructured":"Abushanab D, et al. Projecting the health and economic burden of cardiovascular disease among people with type 2 diabetes, 2022\u20132031. Pharmacoeconomics. 2023;41(6):719\u201332.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"21247_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/pop.2012.0020","volume":"16","author":"D Kent","year":"2013","unstructured":"Kent D, et al. Reducing the risks of diabetes complications through diabetes self-management education and support. Popul Health Manag. 2013;16(2):74\u201381.","journal-title":"Popul Health Manag"},{"key":"21247_CR43","doi-asserted-by":"publisher","first-page":"3086167","DOI":"10.1155\/2018\/3086167","volume":"2018","author":"K Papatheodorou","year":"2018","unstructured":"Papatheodorou K, et al. Complications of Diabetes 2017. J Diabetes Res. 2018;2018:3086167.","journal-title":"J Diabetes Res"},{"key":"21247_CR44","unstructured":"WorldData, Average income around the world. 2022."},{"issue":"10","key":"21247_CR45","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/jama.2018.1151","volume":"319","author":"EJ Emanuel","year":"2018","unstructured":"Emanuel EJ. The real cost of the US health care system. JAMA. 2018;319(10):983\u20135.","journal-title":"JAMA"},{"key":"21247_CR46","unstructured":"Ginsburg, P.B., High and rising health care costs: Demystifying US health care spending. 2008: Synthesis Project, Robert Wood Johnson Foundation."},{"issue":"4","key":"21247_CR47","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2337\/dc20-2871","volume":"44","author":"H Shao","year":"2021","unstructured":"Shao H, et al. Trends in total and out-of-pocket payments for noninsulin glucose-lowering drugs among US adults with large-employer private health insurance from 2005 to 2018. Diabetes Care. 2021;44(4):925\u201334.","journal-title":"Diabetes Care"},{"issue":"7","key":"21247_CR48","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2337\/dc17-1376","volume":"41","author":"E Squires","year":"2018","unstructured":"Squires E, et al. Health care spending on diabetes in the US, 1996\u20132013. Diabetes Care. 2018;41(7):1423\u201331.","journal-title":"Diabetes Care"},{"issue":"1","key":"21247_CR49","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/13696998.2021.1945242","volume":"24","author":"EA Finkelstein","year":"2021","unstructured":"Finkelstein EA, et al. The impact of seven major noncommunicable diseases on direct medical costs, absenteeism, and presenteeism in Gulf Cooperation Council countries. J Med Econ. 2021;24(1):828\u201334.","journal-title":"J Med Econ"},{"issue":"8","key":"21247_CR50","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40273-015-0268-9","volume":"33","author":"T Seuring","year":"2015","unstructured":"Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015;33(8):811\u201331.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"21247_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.107916","volume":"35","author":"L Shi","year":"2021","unstructured":"Shi L, Fonseca V, Childs B. Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. J Diabetes Complications. 2021;35(6): 107916.","journal-title":"J Diabetes Complications"},{"issue":"10","key":"21247_CR52","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/dme.14285","volume":"37","author":"L Janssen","year":"2020","unstructured":"Janssen L, et al. Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study. Diabet Med. 2020;37(10):1759\u201365.","journal-title":"Diabet Med"},{"key":"21247_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-698X-9-1","volume":"9","author":"JM Kirigia","year":"2009","unstructured":"Kirigia JM, et al. Economic burden of diabetes mellitus in the WHO African region. BMC Int Health Hum Rights. 2009;9:1\u201312.","journal-title":"BMC Int Health Hum Rights"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-21247-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-21247-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-21247-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T13:01:50Z","timestamp":1735995710000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-21247-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21247"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-21247-5","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Research Ethics Committees of Endocrine & Metabolism Research Institute\u2014Tehran University of Medical Sciences(IR.TUMS.EMRI.REC.1401.127). The required data were extracted from previous studies on this topic according to the study aims, and consequently, obtaining informed consent was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}